News

Ideas That Generate Results

The growth in pharma markets in emerging countries has outperformed the overall growth of the global pharma market. Brazil is one of the largest pharma markets in Latin America. According to our new research on the sector called "Emerging Pharmaceutical Markets Globally", the pharma market in Brazil is forecast to grow at a CAGR of around 15% during 2009-2012 on the back of various factors like improving economic condition, increasing population, rising prevalence of diseases and improving regulatory environment.

Our research identifies that continuous improvements in macroeconomic environment will drive the growth of pharmaceutical market in the country. Our research provides a complete analysis on macroeconomic factors that are affecting the growth of the market. Besides, the report also provides information on healthcare spending, diseases profile and population profile of the country, which will help clients in identifying the future demand in the market.

We have found that demand for generics will grow at a higher pace in Brazil and all the other emerging countries discussed in the report. Our research includes a detailed description of generics market in all these countries. It also provides a detailed analysis on the factors which are fuelling the growth in sales of generic drugs in these countries. Moreover, the research reveals information on key emerging opportunities like research and manufacturing outsourcing market which are growing in line with the development of pharma markets in these emerging countries.

RNCOS' "Emerging Pharmaceutical Markets Globally" gives an extensive and coherent analysis on the pharma markets of seven emerging countries i.e. Brazil, Russia, India, China, Turkey, Indonesia, and Mexico. It gives complete business information about the key competitors in these markets along with their area of expertise. It also features future direction of the industry supported with facts and figures. Thus, the report serves as a useful guide to pharma companies, investors and consultants who are planning to enter the pharma markets in these countries.

For more information visit: http://www.rncos.com/Report/IM081.htm